Home/ Stocks/ TCRX

TScan Therapeutics, Inc. Common Stock

TCRX XNAS

$1.26 +0.09 (+7.44%) ▲ 15-min delayed

Open

$1.23

High

$1.34

Low

$1.23

Volume

1.28M

Market Cap

$82.34M

About TScan Therapeutics, Inc. Common Stock

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 142 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$982.0K	$-28,666,000	$-0.22
FY 2025	$10.32M	$-129,766,000	$-1.00
Q3 2025	$2.51M	$-35,710,000	$-0.28
Q2 2025	$3.08M	$-36,952,000	$-0.28

Related Market News

No specific coverage for TCRX yet. Check out our latest market news or earnings calendar.

Get TCRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on TScan Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.